Figure 5
Nuclear PKM2 decreases the sensitivity of CRC cells to gefitinib in vivo.
(A,B) The tumor images from the nuclear PKM2 overexpression, PKM2 knockdown, or the control group were determined at the 28th day with or without gefitinib treatment (50 mg/kg/day) and the tumor growth rate were analyzed between the groups. (C) Stattic sensitized HT29/PKM2-NLS cells to gefitinib in vivo. Mice were subcutaneously implanted with HT29/PKM2-NLS cell lines. Mice were administrated with vehicle (saline), Stattic at 10 mg/kg/day, gefitinib at 50 mg/kg/day, or the combination of the 2 drugs for 4 weeks. (D) The TUNEL-positive cells were analyzed in the tumor sections. We counted the number of nuclei that were positively stained to determine the percentage of TUNEL-positive cells in the groups, using three randomly selected fields in each slide. (E) The Ki67-positive cells were analyzed in the tumor sections; the percentage of Ki67-positive cells in the groups was counted.
